Table 1. BRMS1staining and clinicopathological characteristics of 192 glioma patients.
| Variables | BRMS1 staining | |||
| Negative, No. (%) | Positive, No. (%) | Total | P * | |
| Age | ||||
| <46 years | 71(79.8%) | 18(20.2%) | 89 | 0.260 |
| ≥46 years | 75(72.8%) | 28(27.2%) | 103 | |
| Gender | ||||
| Male | 90(76.9%) | 27(23.1%) | 117 | 0.721 |
| Female | 56(74.7%) | 19(25.3%) | 75 | |
| WHO Grade | ||||
| Benign(I–II) | 95(70.9%) | 39(29.1%) | 134 | 0.046 |
| Malignant(III–IV) | 49(84.5%) | 9(15.5%) | 58 | |
| Histologic type | ||||
| Astrocytoma | 105(75.5%) | 34(24.5%) | 139 | 0.704 |
| Glioblastoma | 26(81.2%) | 6(18.8%) | 32 | |
| Oligoastrocytoma | 13(86.7%) | 2(13.3%) | 15 | |
| Ependymoma | 5(83.3%) | 1(16.7%) | 6 | |
*χ2 test.